Clinical Trial

Rituximab in Combination With Glofitamab and Polatuzumab Vedotin in Patients With Previously Untreated Aggressive B-cell Lymphoma Ineligible for R-CHOP

Study acronym: R-Pola-Glo
Active, Not Recruiting Phase 2
View on ClinicalTrials.gov →
Summary
In the present trial the chemotherapy- light treatment concept R-Pola-Glo will be evaluated that combines the anti-CD20 antibody rituximab (R) with the ADC polatuzumab vedotin (Pola) and the (BiMabs) glofitamab (Glo) in elderly and/or medical unfit and previously untreated patients with aggressive B-cell lymphoma. The outcome and feasibility data obtained here will be used for further clinical development of this new chemolight triple combination.
Protocol Amendment History 6 amendments
This ClinicalTrials.gov record has been amended 6 times since 2023-03-22; most recent amendment 2026-04-02.
Status change: Recruiting → Active, Not Recruiting 2025-04-29
Status change: Active, Not Recruiting → Recruiting 2024-11-07
Status change: Recruiting → Active, Not Recruiting 2024-07-24
Status change: Not Yet Recruiting → Recruiting 2023-05-30
Trial Details
NCT Number NCT05798156
Lead Sponsor Institut für Klinische Krebsforschung IKF GmbH at Krankenhaus Nordwest
Collaborators: Charite University, Berlin, Germany, University of Salzburg, Arbeitsgemeinschaft medikamentoese Tumortherapie, Roche Pharma AG, Zentrum für Klinische Studien Leipzig, Hoffmann-La Roche
Conditions Lymphoma, Large B-Cell, Diffuse
Enrollment 125 participants
Start Date 2023-03-20
Primary Completion 2025-04-12 (estimated)
Study Completion 2028-02-28 (estimated)
Updated on ClinicalTrials.gov 2026-04-08